Compass Therapeutics, Inc. CMPX
We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development and commercialization as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $850.0K | $0 | — | — | — | — | — | — |
| R&D | $56.0M | $42.3M | $38.1M | — | — | $14.9M | $22.4M | — | — |
| SG&A | $16.9M | $15.1M | $12.2M | $11.7M | $10.9M | $12.9M | $11.6M | $32.8K | — |
| Total operating expenses | $72.8M | $57.5M | $50.4M | $41.7M | $81.9M | $27.8M | $34.1M | — | — |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M | -$27.8M | -$34.1M | -$32.8K | — |
| Interest expense | — | — | — | $0 | $370.0K | $908.0K | $1.2M | $3.3K | — |
| Pre-tax income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M | -$29.5M | -$34.7M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $32.0K | $91.0K | — | — |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M | -$29.5M | -$34.7M | -$36.0K | — |
| EPS, basic | -0.42 | -0.36 | -0.33 | -0.37 | -1.31 | — | — | — | — |
| EPS, diluted | — | — | — | — | -1.31 | -0.96 | -5.19 | -0.01 | — |
| Shares, diluted (wtd. avg.) | 157.7M | 137.4M | 127.0M | 105.2M | 62.9M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.6M | $43.5M | $24.2M | $34.9M | $144.5M | $47.1M | $25.3M | $4.9K | — |
| Short-term investments | $178.3M | $83.2M | $128.2M | $151.7M | $0 | — | — | — | — |
| Total current assets | $209.8M | $132.8M | $153.9M | $194.8M | $147.1M | $50.2M | $26.2M | $4.9K | $25 |
| Property, plant and equipment | $102.0K | $353.0K | $898.0K | $1.6M | $2.2M | $1.1M | $3.8M | — | — |
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M | $51.9M | $30.4M | $4.9K | $25 |
| Accounts payable | $1.6M | $2.2M | $4.1M | $3.4M | $867.0K | $1.1M | $629.0K | $3.3K | $52 |
| Short-term debt | — | — | — | — | $0 | $7.5M | $5.6M | — | — |
| Total current liabilities | $14.0M | $8.9M | $7.8M | $16.2M | $10.6M | $10.1M | $9.8M | $75.5K | $34.6K |
| Long-term debt | — | — | — | — | $0 | $1.9M | $9.3M | — | — |
| Total liabilities | $22.8M | $15.2M | $8.3M | $18.0M | $13.7M | $12.0M | $19.1M | $75.5K | $34.6K |
| Retained earnings | -$431.2M | -$364.7M | -$315.3M | -$272.8M | -$233.6M | -$151.4M | -$121.9M | -$71.1K | -$35.1K |
| Total equity | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M | $39.9M | $11.3M | -$84.8M | -$34.6K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M | -$26.8M | -$31.7M | -$32.8K | — |
| Depreciation and amortisation | $300.0K | $600.0K | $700.0K | $800.0K | $600.0K | $2.4M | $2.1M | — | — |
| Stock-based compensation | $8.4M | $8.6M | $6.1M | $5.3M | $4.0M | $4.0M | $915.0K | — | — |
| Capital expenditure | $25.0K | $44.0K | $30.0K | $212.0K | $1.6M | $106.0K | $466.0K | — | — |
| Investing cash flow | -$93.3M | $46.8M | $27.0M | -$151.2M | -$1.8M | $38.0K | -$466.0K | — | — |
| Financing cash flow | $129.6M | $17.3M | $2.9M | $75.8M | $118.6M | $48.5M | $31.0K | $37.6K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017649.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $850.0K | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$36.0K | -$34.7M | -$29.5M | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Other event Item 8.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |